The mesh and the surrounding tissue are supposed to grow together, strengthening and reinforcing the area that was torn. The process is supposed to be much more effective than the synthetic versions. The patch is designed to chemically link the proteins in the tissue together.
In some cases, cross-linking has been linked to a risk of foreign body response, according to allegations raised in complaints brought by individuals who have experienced painful and debilitating complications after the surgical mesh was used during a hernia repair.
The mesh is actually treated pig skin. Unfortunately, these cross-linked grafts can cause serious infections and lead to the rejection of the medical device. As of September 2020, the Food and Drug Administration received at least 450 Medical Device Reports linked to such problems caused by the Strattice Hernia Mesh. There were six reports of patient fatalities, approximately 340 reports of injuries, and more than 100 reports that indicated malfunctions of the mesh.
Strattice hernia mesh lawsuits are alleging that the device is defectively designed and the manufacturer failed to warn medical professionals about the serious adverse events associated with the mesh. Additionally, those who have been injured by this mesh allege that the Strattice hernia mesh was marketed in such a fashion as to hide the defective design of the mesh and its potential failure once implanted.
Lifecell Corporation got FDA approval for the biologic mesh in 2007 and it was first sold in 2008. Approval was through the 510k process, which does not require safety and efficacy testing. Allergan, Inc., purchased Lifecell in 2017. Both Lifecell and Allergan are the primary defendants. AbbVie, Inc., purchases Allergan in 2019, but AbbVie is not a primary defendant at this time.
Lawyers at our firm are admitted to practice law in New Jersey, where there are two courts leading the litigation. We have litigated and continue to litigate hernia and pelvic mesh cases in New Jersey state and federal courts.
Due to common questions which have arisen in the various cases, the litigation was centralized and consolidated before New Jersey Superior Court Judge John C. Porto in Atlantic County in October 2021, as part of a multi-county litigation (MCL), which is intended to reduce duplicate discovery and avoid conflicting pretrial rulings from different judges. A trial is set for January 2024.
There is a parallel Strattice litigation before Judge Brian Martinotti in the United States District Court for the District of New Jersey. Judge Martinotti has extensive product liability experience and there could also be 2024 trials in federal court.
Our firm has been reviewing potential claims for the last fifteen years. We know each client has been affected in unique, individual ways. Every client has their own individual case which takes into account your specific damages for pain & suffering, scarring, lost earnings, emotional damages, out-of-pocket expenses, and whatever else has been affected.
We will discuss with you, at no charge, what your operative reports and medical records show as far as a defective product. We will also discuss possible litigation strategies. Defendants rarely “do the right thing” and settle cases out of court. It often takes aggressive litigation to resolve a claim fairly for your unique situation.
The allegations presented in this litigation are different than those raised in other lawsuits over hernia mesh filed in recent years over products made with polypropylene. There are tens of thousands of Ethicon Physiomesh lawsuits, Atrium C-Qur mesh lawsuits, Bard hernia patch lawsuits and similar claims alleging that design defects resulted in painful and complications.
Our firm is litigating these meshes, with our firm handling mesh litigation for the last fifteen years. Strattice mesh lawsuits allege that similar problems have been linked to this product, with a focus on the unique failure aspects of biologic meshes.